June's List of Pharmaceutical Events: Multiple Heavyweight Rankings Changed

"
Pharmaceutical Network Industry Dynamic" Unknowingly, June has come to an end, meaning that the first half of 2020 will be completed, will also be the second half of the pharmaceutical industry to pave the way for the developmentThis month, there are a number of medical list, including heavyweight listFor example, the Global Pharmaceutical Company Top 50 2020, published by Pharm Exec, usa, and GlobalData's ranking of top20 innovative pharmaceutical companies in the first quarter of 2020Four Chinese pharmaceutical companies were selected for the "Top 50 Global Pharmaceutical Company 2020"June, and pharmExec published the 2020 top50 list of global pharmaceutical companiesThe list is a list focused on prescription drug sales, which reflects the global pharmaceutical industry's revenue and overall strength, and is a miniature version of the Fortune 500 pharmaceutical industrytop 50 list, China's Hengrui Pharmaceuticals, China Biopharma (zhengda Tianqing's parent company), Yunnan White Pharmaceuticals, Shanghai Pharmaceuticals, four pharmaceutical companies entered the listAmong them, Yunnan White Medicine and Shanghai Pharma are the new list editing enterprises this year, ranking 37th and 48th, respectivelyIt is also evidence that the revenues and strength of Chinese pharmaceutical companies are growingIn 2019, chemicalAPIenterprise revenue top10
According to the same flower shun ifind data, 2019 chemical API sector a total of 29 listed enterprises, all achieved profitability From the 2019 chemical API enterprise revenue top ten list, ST Crown, Haizheng Pharmaceuticals, Xinhecheng, Plo Pharmaceuticals, Zhejiang Pharmaceuticals, Xinhua Pharmaceuticals, Yifan Pharmaceuticals, Haipri, Jindawei, Haixiang Pharmaceuticals list of which in 2019 the top 10 list of chemical API enterprises revenue, two chemical API enterprises revenue of more than 10 billion yuan, respectively, ST Guanfu and Haizheng Pharmaceuticals The 2019 pharmaceutical company executive pay list was revealed
according to the number of outlet scantily- incomplete statistics, in 2019, 33 pharmaceutical companies' chairman's annual salary of more than 2 million, the same performance as in 2018, including Meirui Medical Chairman Li Xiting with an annual salary of more than 20 million, pharmaceutical company chairman Li Gepay followed, And Fosun Pharmaceutical's Yao Fang, Chen Qiyu ranked third According to the author combing, in 2019 a total of five pharmaceutical company executives ranked in the "million compensation club", including Meirui Medical Chairman Li Xiting, Meirui Medical General Manager Cheng Minghe, Pharmaceutical MingKang Chairman and General Manager Li Ge, Fosun Pharmaceutical chairman Yao Fang, Chen Qiyu Top20 Innovative PharmaceuticalS Market Capitalization Rankings for the first quarter of 2020 data analysis and consulting firm GlobalData released market capitalization rankings and changes for TOP20 Innovative PharmaceuticalS in the first quarter of 2020 The global top 20 drugmaker's total market capitalization fell 7.9 percent to about $2.6 trillion compared with the fourth quarter of the previous year , 13 of the TOP20 drugmakers saw their market value decline, with Bayer down 28.5 percent, followed by GlaxoSmithKline (16.7 percent), Amgen (16.5 percent), Pfizer (16.5 percent), Baxter (16.2 percent) and Mercato (15.7 percent) The top three have also changed, with Pfizer's new ranking dropping from "Big Brother" to fifth place, plummeting Johnson and Johnson, Roche and Novartis are the top three Top20 the profits of listed Chinese medicine enterprises held a meeting of the Chinese Chinese Medicine Association to summarize the performance of listed companies in Chinese medicine manufacturing in 2019 According to the ranking of the top 20 companies in profit, Yunnan White Pharmaceutical ranked first with a net profit of 4.18 billion yuan, with net profit increasing by 19.75 percent year-on-year in 2019 The 2019 ranking also changed relatively much compared with the previous year, mainly reflected in the "three into three out": Red Day Pharmaceuticals, Shenwei Pharmaceuticals and Guilin Sanjin 3 enterprises newly entered the top 20, Dong'a gu, Kang Enbei and Guizhou Bailing exit Top10 the number of financing transactions completed in the first quarter of 2020
the number of RMB financing transactions fell to 541 in the first quarter of 2020, down about 46.7% from the same period in the first quarter of 2019 In the number of domestic financing transactions completed TOP10, there are 3 pharmaceutical-related industries, of which biotechnology and pharmaceutical with 41 ranking; Three industries completed a total of 70 financing transactions, accounting for 12.9% of the total amount of financing transactions, performance is bright